Weekly paclitaxel plus estramustine combination therapy in hormone‐refractory prostate cancer: A pilot study
暂无分享,去创建一个
S. Egawa | E. Yokoyama | S. Baba | H. Kuruma | T. Fujita | T. Shitara
[1] K. Shigeno,et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. , 2002, The Journal of urology.
[2] M. Zahurak,et al. Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma , 2002, Cancer.
[3] K. Yamaguchi. Overview of cancer control programs in Japan. , 2002, Japanese journal of clinical oncology.
[4] K. Ushijima,et al. Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study. , 2001, Japanese journal of clinical oncology.
[5] G. Hudes,et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. , 2001, Urology.
[6] B. Redman,et al. Weekly 1‐hour infusion of paclitaxel , 2000, Cancer.
[7] W. Oh. Chemotherapy for patients with advanced prostate carcinoma , 2000, Cancer.
[8] D. Petrylak,et al. Chemotherapy for advanced hormone refractory prostate cancer. , 1999, Urology.
[9] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Budman,et al. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. , 1999, Seminars in oncology.
[11] C. Hudis,et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Litwin,et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Ozols,et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] D. Strumberg,et al. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. , 1996, European journal of cancer.
[15] G. Hudes,et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. , 1995, Seminars in oncology.
[16] M. Egorin,et al. Paclitaxel pharmacokinetics and pharmacodynamics. , 1995, Seminars in oncology.
[17] B. Yeap,et al. Taxol in advanced, hormone‐refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group , 1993, Cancer.
[18] B. Dahllöf,et al. Estramustine depolymerizes microtubules by binding to tubulin. , 1993, Cancer research.
[19] K. Tew,et al. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. , 1992, Cancer research.
[20] S. Vogelgesang,et al. Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate. , 1988, The Journal of urology.
[21] D. Citrin,et al. Estramustine affects bone mineral metabolism in metastatic prostate cancer , 1986, Cancer.
[22] C. Coleman,et al. Clinical radiosensitization: why it does and does not work. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Choy,et al. Phase I trial of weekly paclitaxel in advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Norton,et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B R Goldspiel,et al. Paclitaxel (Taxol) , 1994, Pharmacotherapy.